[
  {
    "ts": null,
    "headline": "Is Now the Best Time to Buy Pfizer Stock?",
    "summary": "It's worth taking a second look at the healthcare giant.",
    "url": "https://finnhub.io/api/news?id=03eefc0f3ed0058a06b24249e89f040952adfffbd3132b8dcd46ce9f89ea8077",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770836880,
      "headline": "Is Now the Best Time to Buy Pfizer Stock?",
      "id": 139047946,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "It's worth taking a second look at the healthcare giant.",
      "url": "https://finnhub.io/api/news?id=03eefc0f3ed0058a06b24249e89f040952adfffbd3132b8dcd46ce9f89ea8077"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Reports Strong Earnings Outlook - Unusual Call Options Activity Shows Investors are Bullish",
    "summary": "Pfizer reported strong earnings and earnings guidance. Large, unusual call option activity today, as noted in a Barchart report, indicates investors are bullish.",
    "url": "https://finnhub.io/api/news?id=097947e0d0777be5a60cab346730cb7ff005020f962c456e8150ddeb0e759900",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770834602,
      "headline": "Pfizer Reports Strong Earnings Outlook - Unusual Call Options Activity Shows Investors are Bullish",
      "id": 139049551,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer reported strong earnings and earnings guidance. Large, unusual call option activity today, as noted in a Barchart report, indicates investors are bullish.",
      "url": "https://finnhub.io/api/news?id=097947e0d0777be5a60cab346730cb7ff005020f962c456e8150ddeb0e759900"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: A Great Opportunity Post Earnings",
    "summary": "Pfizer Inc. remains a Strong Buy, offering compelling value with a 6.32% dividend yield and a P/E Non-GAAP of 8.43. Learn more about PFE stock here.",
    "url": "https://finnhub.io/api/news?id=8e3931c8fec43fa237de8abc9d559f46a2d1744edad4b12f1bedbfeea684327a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770833286,
      "headline": "Pfizer: A Great Opportunity Post Earnings",
      "id": 139050218,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1292440985/image_1292440985.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Pfizer Inc. remains a Strong Buy, offering compelling value with a 6.32% dividend yield and a P/E Non-GAAP of 8.43. Learn more about PFE stock here.",
      "url": "https://finnhub.io/api/news?id=8e3931c8fec43fa237de8abc9d559f46a2d1744edad4b12f1bedbfeea684327a"
    }
  },
  {
    "ts": null,
    "headline": "Pharma companies left out of Trump's drug-pricing deals look for way in",
    "summary": "SAN FRANCISCO, Feb 11 (Reuters) - Some pharmaceutical companies not targeted by President Donald Trump for agreements to lower their U. drug pricing are looking to craft their own deals in an attempt to avoid potentially onerous tariffs and new price-setting schemes, according to six industry sources.",
    "url": "https://finnhub.io/api/news?id=76636b34822603519183bdedc54a04d72ac40c8343f83bf7b8ba9046f79f10d1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770832672,
      "headline": "Pharma companies left out of Trump's drug-pricing deals look for way in",
      "id": 139047279,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "SAN FRANCISCO, Feb 11 (Reuters) - Some pharmaceutical companies not targeted by President Donald Trump for agreements to lower their U. drug pricing are looking to craft their own deals in an attempt to avoid potentially onerous tariffs and new price-setting schemes, according to six industry sources.",
      "url": "https://finnhub.io/api/news?id=76636b34822603519183bdedc54a04d72ac40c8343f83bf7b8ba9046f79f10d1"
    }
  },
  {
    "ts": null,
    "headline": "2 Urgent Sells And 2 No Brainer Dividend Buys",
    "summary": "It is in our best approach to sell high and buy low. Here's how to approach it systematically today with 2 SELLS and 2 BUYS. Read the full article here.",
    "url": "https://finnhub.io/api/news?id=710180ef6607cf998857b15aaa54b1cbd366e4e984f58dca1a1a55930c6f0ac2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770826010,
      "headline": "2 Urgent Sells And 2 No Brainer Dividend Buys",
      "id": 139048960,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2396885/image_2396885.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "It is in our best approach to sell high and buy low. Here's how to approach it systematically today with 2 SELLS and 2 BUYS. Read the full article here.",
      "url": "https://finnhub.io/api/news?id=710180ef6607cf998857b15aaa54b1cbd366e4e984f58dca1a1a55930c6f0ac2"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer (PFE) Closes 2025 on Solid Note, Returns $9.8B to Shareholders",
    "summary": "Pfizer Inc. (NYSE:PFE) is included among the Dividend Champions, Contenders, and Challengers List: 15 Highest Yielding Stocks. Pfizer Inc. (NYSE:PFE) reported its Q4 2025 results on February 3. The company posted revenue of $17.56 billion, falling slightly by 1.1% from a year earlier. On the earnings call, Chairman and CEO Albert Bourla asserted that the […]",
    "url": "https://finnhub.io/api/news?id=45a3b02a4db2bad370f354fa07b4cfb2bb66d8486d4c3ae413e2242a8e0ba131",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770824105,
      "headline": "Pfizer (PFE) Closes 2025 on Solid Note, Returns $9.8B to Shareholders",
      "id": 139045155,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer Inc. (NYSE:PFE) is included among the Dividend Champions, Contenders, and Challengers List: 15 Highest Yielding Stocks. Pfizer Inc. (NYSE:PFE) reported its Q4 2025 results on February 3. The company posted revenue of $17.56 billion, falling slightly by 1.1% from a year earlier. On the earnings call, Chairman and CEO Albert Bourla asserted that the […]",
      "url": "https://finnhub.io/api/news?id=45a3b02a4db2bad370f354fa07b4cfb2bb66d8486d4c3ae413e2242a8e0ba131"
    }
  },
  {
    "ts": null,
    "headline": "Healthcare Stocks Are Sinking. Here Are 2 to Buy on the Dip.",
    "summary": "Eli Lilly is priced for perfection thanks to its GLP-1 drugs, while Wall Street seems to have forgotten about these two high-yield healthcare stocks.",
    "url": "https://finnhub.io/api/news?id=e454174031cbd5f147537242509ca8f4f827acefbc8ceb6c7d19ed9073317485",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770824100,
      "headline": "Healthcare Stocks Are Sinking. Here Are 2 to Buy on the Dip.",
      "id": 139044984,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Eli Lilly is priced for perfection thanks to its GLP-1 drugs, while Wall Street seems to have forgotten about these two high-yield healthcare stocks.",
      "url": "https://finnhub.io/api/news?id=e454174031cbd5f147537242509ca8f4f827acefbc8ceb6c7d19ed9073317485"
    }
  },
  {
    "ts": null,
    "headline": "Can Pfizer's New & Acquired Drugs Offset Its Looming Patent Cliff?",
    "summary": "PFE bets on new and acquired drugs to reignite growth as COVID sales fade and a 2026-2030 patent cliff threatens key blockbusters.",
    "url": "https://finnhub.io/api/news?id=e63a3df62afc845d15449875b0c97ba9473a738a02341da68a397776a2693a6d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770815340,
      "headline": "Can Pfizer's New & Acquired Drugs Offset Its Looming Patent Cliff?",
      "id": 139045076,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "PFE bets on new and acquired drugs to reignite growth as COVID sales fade and a 2026-2030 patent cliff threatens key blockbusters.",
      "url": "https://finnhub.io/api/news?id=e63a3df62afc845d15449875b0c97ba9473a738a02341da68a397776a2693a6d"
    }
  },
  {
    "ts": null,
    "headline": "CorMedix Banks on DefenCath Sales in Q4 as Melinta Adds Upside",
    "summary": "CRMD heads into Q4 earnings with DefenCath driving revenues, boosted by strong outpatient dialysis use and added contributions from acquired Melinta products.",
    "url": "https://finnhub.io/api/news?id=ff425969ba882ea6ba219a97c30421481f114b4c36b093eebfe956a1682838e2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770814860,
      "headline": "CorMedix Banks on DefenCath Sales in Q4 as Melinta Adds Upside",
      "id": 139045158,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "CRMD heads into Q4 earnings with DefenCath driving revenues, boosted by strong outpatient dialysis use and added contributions from acquired Melinta products.",
      "url": "https://finnhub.io/api/news?id=ff425969ba882ea6ba219a97c30421481f114b4c36b093eebfe956a1682838e2"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers: Walking Blindfolded To A $30 Billion Patent Cliff",
    "summary": "All eyes should be on Bristol-Myers' upcoming $30B patent cliff as the Growth portfolio lost significant potential. Read why BMY stock is downgraded to Hold.",
    "url": "https://finnhub.io/api/news?id=998c1f1316cfb5204c61b1045a95674a0852fcfbc9266365137c83389a04252f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770804000,
      "headline": "Bristol-Myers: Walking Blindfolded To A $30 Billion Patent Cliff",
      "id": 139044801,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/158759380/image_158759380.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "All eyes should be on Bristol-Myers' upcoming $30B patent cliff as the Growth portfolio lost significant potential. Read why BMY stock is downgraded to Hold.",
      "url": "https://finnhub.io/api/news?id=998c1f1316cfb5204c61b1045a95674a0852fcfbc9266365137c83389a04252f"
    }
  }
]